- 0
Highlights & Basics
- Malignant pleural mesothelioma accounts for most malignant mesotheliomas; it is a rare malignancy with an annual incidence of approximately 0.7 per 100,000 people in the US.
- Largely caused by exposure to asbestos, with a 20- to 40-year latency period between exposure and the development of malignancy; the typical patient is in the sixth to ninth decade of life.
- Most patients present with shortness of breath and chest pain, which on investigation is often found to be associated with unilateral pleural effusion and pleural thickening.
- Despite advances in treatment, malignant pleural mesothelioma remains a highly lethal malignancy with few long-term survivors.
- Operable malignant disease should receive trimodal therapy with chemotherapy, surgery, and hemithoracic radiation therapy.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Chest x-ray demonstrating total left-sided collapse and replacement of hemithorax with mesothelioma; there is reduced expansion on this side
Computed tomography scan of the lung showing a right-sided pleural mesothelioma and left-sided calcified pleural plaque
Computed tomography scan of the mediastinum showing a right-sided pleural mesothelioma and left-sided calcified pleural plaque
Positron emission tomography scan showing hypermetabolic right-sided pleural mesothelioma
Citations
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: mesothelioma: pleural [internet publication].[Full Text]
Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018 Mar;73(suppl 1):i1-30.[Abstract][Full Text]
Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Feb;33(2):129-42.[Abstract][Full Text]
Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018 May 1;36(13):1343-73.[Abstract][Full Text]
1. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012 Jan;227(1):44-58.[Abstract][Full Text]
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: mesothelioma: pleural [internet publication].[Full Text]
3. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022 May;17(5):608-22.[Abstract][Full Text]
4. National Cancer Institute. Mesothelioma: recent trends in SEER age-adjusted incidence rates, 2000-2022. Apr 2025 [internet publicaton].[Full Text]
5. Health and Safety Executive. Mesothelioma statistics for Great Britain, 2024. Nov 2024 [internet publication].[Full Text]
6. Nishikawa K, Takahashi K, Karjalainen A, et al. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect. 2008 Dec;116(12):1675-80.[Abstract][Full Text]
7. Zhu W, Liu J, Li Y, et al. Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades. SSM Popul Health. 2023 Sep;23:101441.[Abstract][Full Text]
8. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004 Mar;125(3):1103-17.[Abstract]
9. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996;14(5):466-80.[Abstract]
10. Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002 Mar-Apr;26(2):55-65.[Abstract]
11. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol. 2004 Jan 15;159(2):107-12.[Abstract][Full Text]
12. Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000 Dec;44(8):565-601.[Abstract][Full Text]
13. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer. 2013 Mar;13(3):153-9.[Abstract][Full Text]
14. Goodman JE, Nascarella MA, Valberg PA. Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control. 2009 Oct;20(8):1237-54.[Abstract]
15. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001 Feb 10;357(9254):444-5.[Abstract]
16. Congedo MT, West EC, Evangelista J, et al. The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review. J Thorac Dis. 2024 Jan 30;16(1):671-87.[Abstract][Full Text]
17. Aoe K, Hiraki A, Murakami T, et al. Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan. Cancer Sci. 2006 Apr;97(4):292-5.[Abstract][Full Text]
18. Carbone M, Pass HI, Rizzo P, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene. 1994 Jun;9(6):1781-90.[Abstract]
19. Mazzoni E, Bononi I, Rotondo JC, et al. Sera from patients with malignant pleural mesothelioma tested positive for IgG antibodies against SV40 large T antigen: the viral oncoprotein. J Oncol. 2022;2022:7249912.[Abstract][Full Text]
20. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011 Aug 28;43(10):1022-5.[Abstract][Full Text]
21. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011 Jun 5;43(7):668-72.[Abstract][Full Text]
22. Peterson JT Jr, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984 Sep 1;54(5):951-60.[Abstract]
23. Toyokuni S. Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis. Redox Rep. 2014 Jan;19(1):1-7.[Abstract]
24. Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009 Apr;153(4):143-52.[Abstract]
25. Sahu RK, Ruhi S, Jeppu AK, et al. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front Oncol. 2023;13:1204722.[Abstract][Full Text]
26. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15;75(2):264-9.[Abstract][Full Text]
27. Neragi-Miandoab S, Sugarbaker DJ. Chromosomal deletion in patients with malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):42-4.[Abstract][Full Text]
28. Cakiroglu E, Senturk S. Genomics and functional genomics of malignant pleural mesothelioma. Int J Mol Sci. 2020 Sep 1;21(17):6342.[Abstract][Full Text]
29. Harington JS, Wagner JC, Smith M. The detection of hyaluronic acid in pleural fluids of cases with diffuse pleural mesotheliomas. Br J Exp Pathol. 1963 Feb;44:81-3.[Abstract]
30. Wagner JC. The discovery of the association between blue asbestos and mesotheliomas and the aftermath. Br J Ind Med. 1991 Jun;48(6):399-403.[Abstract][Full Text]
31. Olsen NJ, Franklin PJ, Reid A, et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust. 2011 Sep 5;195(5):271-4.[Abstract][Full Text]
32. Park EK, Yates DH, Hyland RA, et al. Asbestos exposure during home renovation in New South Wales. Med J Aust. 2013 Sep 16;199(6):410-3.[Abstract]
33. Visci G, Rizzello E, Zunarelli C, et al. Relationship between exposure to ionizing radiation and mesothelioma risk: a systematic review of the scientific literature and meta-analysis. Cancer Med. 2022 Feb;11(3):778-89.[Abstract][Full Text]
34. Farioli A, Ottone M, Morganti AG, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med. 2016 May;5(5):950-9.[Abstract][Full Text]
35. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009 Apr 16;113(16):3679-81.[Abstract][Full Text]
36. Chirieac LR, Barletta JA, Yeap BY, et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013 Dec 20;31(36):4544-9.[Abstract][Full Text]
37. Alchami FS, Attanoos RL, Gibbs A, et al. Does simian virus 40 (SV40) have a role in UK malignant pleural mesothelioma? no role is identified in a sensitive RNA in situ hybridization study on potentially affected birth cohorts. Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):444-7.[Abstract]
38. Neri M, Ugolini D, Boccia S, et al. Chemoprevention of asbestos-linked cancers: a systematic review. Anticancer Res. 2012 Mar;32(3):1005-13.[Abstract]
39. US Preventive Services Task Force. Vitamin, mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: preventive medication. Jun 2022 [internet publication].[Full Text]
40. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996 May 2;334(18):1150-5.[Abstract][Full Text]
41. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994 Apr 14;330(15):1029-35.[Abstract][Full Text]
42. Occupational Safety and Health Administration. Asbestos: evaluating and controlling exposure [internet publication].[Full Text]
43. American College of Radiology. ACR appropriateness criteria: chronic dyspnea-noncardiovascular origin. 2024 [internet publication].[Full Text]
44. Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018 Mar;73(suppl 1):i1-30.[Abstract][Full Text]
45. Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Feb;33(2):129-42.[Abstract][Full Text]
46. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Apr 2025 [internet publication].[Full Text]
47. Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018 May 1;36(13):1343-73.[Abstract][Full Text]
48. Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990 Mar;154(3):487-92.[Abstract][Full Text]
49. Katz SI, Straus CM, Roshkovan L, et al. Considerations for imaging of malignant pleural mesothelioma: a consensus statement from the International Mesothelioma Interest Group. J Thorac Oncol. 2023 Mar;18(3):278-98.[Abstract][Full Text]
50. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997 Jan;111(1):106-9.[Abstract]
51. Shield PW, Koivurinne K. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology. 2008 Aug;19(4):218-23.[Abstract]
52. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002 Jan;15(1):6-10.[Abstract]
53. US Food & Drug Administration. Fujirebio Mesomark assay. Humanitarian device exemption (HDE). H060004. Jan 2007 [internet publication].[Full Text]
54. Zhu M, Lu Z, Guo H, et al. Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis. Front Oncol. 2023;13:1136049.[Abstract][Full Text]
55. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94.[Abstract][Full Text]
56. Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004 Jan-Feb;24(1):105-19.[Abstract][Full Text]
57. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Mar 20;27(9):1413-8.[Abstract]
58. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005 Nov;129(11):1421-7.[Abstract]
59. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004 Sep 15;170(6):691-715.[Abstract][Full Text]
60. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995 Oct;108(4):1122-8.[Abstract]
61. Edge SB, Greene FL, Byrd DR, et al., eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.
62. Blum TG, Morgan RL, Durieux V, et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J. 2023 Feb 16;61(2):2103201.[Abstract][Full Text]
63. Alnajar A, Kareff SA, Razi SS, et al. Disparities in survival due to social determinants of health and access to treatment in US patients with operable malignant pleural mesothelioma. JAMA Netw Open. 2023 Mar 1;6(3):e234261.[Abstract][Full Text]
64. Thieke C, Nicolay NH, Sterzing F, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015 Dec 30;10:267.[Abstract][Full Text]
65. Lococo F, Torricelli F, Lang-Lazdunski L, et al. Survival results in biphasic malignant pleural mesothelioma patients: a multicentric analysis. J Thorac Cardiovasc Surg. 2020 Apr;159(4):1584-93.[Abstract][Full Text]
66. Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024 Jun;12(6):457-66.[Abstract][Full Text]
67. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9.[Abstract]
68. Zellos L, Jaklitsch MT, Al-Mourgi MA, et al. Complications of extrapleural pneumonectomy. Semin Thorac Cardiovasc Surg. 2007 Winter;19(4):355-9.[Abstract]
69. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3.[Abstract]
70. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011 Aug;12(8):763-72.[Abstract][Full Text]
71. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20;27(18):3007-13.[Abstract]
72. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006 May;1(4):289-95.[Abstract]
73. Weder W, Stahel RA, Bernhard J, et al; Swiss Group for Clinical Cancer Research. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007 Jul;18(7):1196-202.[Abstract][Full Text]
74. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer. 2008 Jul 8;99(1):44-50.[Abstract][Full Text]
75. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8.[Abstract][Full Text]
76. Green J, Dundar Y, Dodd S, et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005574.[Abstract][Full Text]
77. Zalcman G, Mazieres J, Margery J, et al; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14.[Abstract]
78. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020 Dec;31(12):1734-45.[Abstract][Full Text]
79. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-306.[Abstract]
80. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30;397(10272):375-386.[Abstract]
81. Waliany S, Lee D, Witteles RM, et al. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:113-34.[Abstract][Full Text]
82. Nielsen DL, Juhl CB, Nielsen OH, et al. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol. 2024 Oct 1;10(10):1390-9.[Abstract]
83. Wu L, Tsang V, Menzies AM, et al. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023 Jun 1;46(6):1292-9.[Abstract][Full Text]
84. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007 Jan 1;109(1):93-9.[Abstract]
85. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-7.[Abstract]
86. Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008 Apr 1;112(7):1555-61.[Abstract]
87. Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 Oct;22(10):1438-47.[Abstract]
88. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov;84(5):1685-92.[Abstract]
89. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5.[Abstract]
90. Rimner A, Zauderer MG, Gomez DR, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016 Aug 10;34(23):2761-8.[Abstract]
91. Patel R, Ludmir EB, Miccio JA, et al. Disease-related outcomes and toxicities of intensity modulated radiation therapy after lung-sparing pleurectomy for malignant pleural mesothelioma: a systematic review. Pract Radiat Oncol. 2020 Nov-Dec;10(6):423-33.[Abstract]
92. Shaikh F, Zauderer MG, von Reibnitz D, et al. Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2017 Jun;12(6):993-1000.[Abstract][Full Text]
93. Trovo M, Relevant A, Polesel J, et al. Radical hemithoracic radiotherapy versus palliative radiotherapy in non-metastatic malignant pleural mesothelioma: results from a phase 3 randomized clinical trial. Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1368-76.[Abstract]
94. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1045-52.[Abstract]
95. Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002 Dec;124(6):1183-9.[Abstract]
96. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995 Sep;108(3):754-8.[Abstract]
97. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004 Jul 5;91(1):9-10.[Abstract][Full Text]
98. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007 Jul;84(1):18-22.[Abstract]
99. Nagendran M, Pallis A, Patel K, et al. Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? Interact Cardiovasc Thorac Surg. 2011 Jul;13(1):66-9.[Abstract][Full Text]
100. Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016 Aug;17(8):1094-104.[Abstract][Full Text]
101. Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018 Sep;6(9):671-80.[Abstract]
102. Dipper A, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2020 Apr 21;4(4):CD010529.[Abstract][Full Text]
103. Rintoul RC, Ritchie AJ, Edwards JG, et al.; MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014 Sep 20;384(9948):1118-27.[Abstract]
104. Rueda JR, Solà I, Pascual A, et al. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD004282.[Abstract][Full Text]
105. Hui D, Bohlke K, Bao T, et al. Management of dyspnea in advanced cancer: ASCO Guideline. J Clin Oncol. 2021 Apr 20;39(12):1389-411.[Abstract][Full Text]
106. Brims F, Gunatilake S, Lawrie I, et al. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019 Apr;74(4):354-61.[Abstract][Full Text]
107. Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024 Apr 1;10(4):475-83.[Abstract][Full Text]
108. National Cancer Institute Surveillance, Epidemiology, and End Results Program. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2020. By sex, delay-adjusted SEER incidence rate, all races/ethnicities, all ages. SEER*Explorer: an interactive website for SEER cancer statistics. Jun 2023 [internet publication].[Full Text]
109. Kristensen CA, Nottrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol. 2009 Jul;92(1):96-9.[Abstract]
110. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7.[Abstract]
111. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44.[Abstract]
112. Bian Z, Zhang R, Yuan S, et al. Healthy lifestyle and cancer survival: a multinational cohort study. Int J Cancer. 2024 May 15;154(10):1709-18.[Abstract][Full Text]
113. Centers for Disease Control and Prevention. Adult immunization schedule by medical condition and other indication: recommendations for ages 19 years or older, United States, 2025. Nov 2023 [internet publication].[Full Text]
114. UK Health Security Agency. Guidance on complete routine immunisation schedule. Jan 2025 [internet publication].[Full Text]
115. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.[Abstract][Full Text]
116. Roeland EJ, Bohlke K, Baracos VE, et al. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 1;41(25):4178-9.[Abstract][Full Text]
117. Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO clinical practice guidelines(☆). ESMO Open. 2021 Jun;6(3):100092.[Abstract][Full Text]
118. Yule MS, Brown LR, Waller R, et al. Cancer cachexia. BMJ. 2024 Oct 23;387:e080040.
119. Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2023 Oct 1;41(28):4562-91.[Abstract][Full Text]
120. Grassi L, Zachariae R, Caruso R, et al. Insomnia in adult patients with cancer: ESMO clinical practice guideline. ESMO Open. 2023 Dec;8(6):102047.[Abstract][Full Text]
